Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost‐effectiveness analysis in the United States and in China

Author:

Liao Xiaodong12,Wu Yajing12,Lin Dong12,Gu Dian3,Luo Shaohong12,Huang Xiaoting12,Xu Xiongwei12,Weng Xiuhua12ORCID,Lin Shen12

Affiliation:

1. Department of Pharmacy the First Affiliated Hospital of Fujian Medical University Fuzhou China

2. Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital Fujian Medical University Fuzhou China

3. Institute for Health & Aging University of California San Francisco California USA

Abstract

AbstractPurposeTo investigate the cost‐effectiveness of lenvatinib plus pembrolizumab (LP) compared to chemotherapy as a second‐line treatment for advanced endometrial cancer (EC) from the United States and Chinese payers' perspective.MethodsIn this economic evaluation, a partitioned survival model was constructed from the perspective of the United States and Chinese payers. The survival data were derived from the clinical trial (309‐KEYNOTE‐775), while costs and utility values were sourced from databases and published literature. Total costs, quality‐adjusted life years (QALYs) and incremental cost‐effectiveness ratio (ICER) were estimated. The robustness of the model was evaluated through sensitivity analyses, and price adjustment scenario analyses was also performed.ResultsBase‐case analysis indicated that LP wouldn't be cost‐effective in the United States at the WTP threshold of $200 000, with improved effectiveness of 0.75 QALYs and an additional cost of $398596.81 (ICER $531392.20). While LP was cost‐effective in China, with improved effectiveness of 0.75 QALYs and an increased overall cost of $62270.44 (ICER $83016.29). Sensitivity analyses revealed that the above results were stable. The scenario analyses results indicated that LP was cost‐effective in the United States when the prices of lenvatinib and pembrolizumab were simultaneously reduced by 61.95% ($26.5361/mg for lenvatinib and $19.1532/mg for pembrolizumab).ConclusionLP isn't cost‐effective in the patients with advanced previously treated endometrial cancer in the United States, whereas it is cost‐effective in China. The evidence‐based pricing strategy provided by this study could benefit decision‐makers in making optimal decisions and clinicians in general clinical practice. More evidence about budget impact and affordability for patients is needed.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3